Correlation between Baseline Characteristics and Clinical Outcomes in a Large Population of Diabetes Patients Treated with Liraglutide in a Real-World Setting in Italy

Clinical Therapeutics

Volumn 37, Issue 3, 2015, Pages 574-584

  Lapolla, Annunziata ^a   Frison, Vera ^b   Bettio, Michela ^b   Pos, Michela Dal ^b   Rocchini, Paola ^b   Panebianco, Giuseppe ^c   Tadiotto, Federica ^c   Tos, Virgilio Da ^c   Dambrosio, Michele ^c   Marangoni, Alberto ^d   Ferrari, Maria ^d   Pianta, Alessandro ^d   Balzano, Sara ^d   Confortin, Loris ^e   Lamonica, Mario ^e   Marin, Narciso ^e   Strazzabosco, Marco ^f   Brun, Elisabetta ^f   Mesturino, Chiara Alberta ^f   Simoncini, Maria ^f   Zen, Francesco ^f   Bax, Giuseppe ^a   Bonsembiante, Barbara ^a   Cardone, Claudio ^a   Dal Frà, Maria Grazia ^a   Gallo, Alessandra ^a   Masin, Michela ^a   Piarulli, Francesco ^a   Sartore, Giovanni ^a   Simioni, Natalino ^b   more..

^a UNIVERSITY OF PADOVA   (Italy)

^b Azienda ULSS 15 Alta Padovana   (Italy)

^c ULSS   (Italy)

^d S Bassiano Hospital   (Italy)

^e S Giacomo Hospital   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

Author keywords

GLP 1; glycemic control; liraglutide; type 2 diabetes; weight loss.

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LIPID;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE DURATION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; AGED; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MULTICENTER STUDY; RETROSPECTIVE STUDY;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ITALY; LIPIDS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84926163580     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.11.015     Document Type: Article

References (23)

1. Standards of Medical Care in Diabetes 2012 Diabetes Care 35 2012 S11 S63
2. L. Sibal, and P.D. Home Management of type 2 diabetes: NICE guidelines Clin Med (Northfield Il) 9 2009 353 357
3. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes, 2012 2012 International Diabetes Federation Brussels, Belgium
4. I.M. Stratton, A.I. Adler, A.W. Neil on behalf of the UK Prospective Diabetes Study Group Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 7258 2000 405 412
5. S.C. Inzucchi, R.M. Bergenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of ADA and EASD Diabetes Care 35 2012 1364 1379
6. S. Cornell Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes J Clin Pharm Ther 37 2012 510 524
7. B. Gallwitz Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents Drugs 71 2011 1675 1688
8. L. Farilla, A. Bulotta, and B. Hirshberg Glucagon-like peptide 1 inhibits cell apoptosis and improve glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149 5158
9. S. Bregenholt, A. Møldrup, and N. Blume The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro Biochem Biophys Res Commun 330 2005 577 584
10. B.L. Wajchenberg β-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr Rev 28 2007 187 218
11. S. Cernea The role of incretin therapy at different stages of diabetes Rev Diabet Stud 8 2011 323 338
12. M.A. Nauck The design of the liraglutide clinical trial programme Diabetes Obes Metab 14 Suppl 2 2012 4 12
13. B. Bode An overview of the pharmacokinetics, efficacy and safety of liraglutide Diabetes Res Clin Pract 97 1 2012 27 42
14. Standard Italiani AMD-SID per la Cura del Diabete Mellito. 2014. http://www.standarditaliani.it/skin/www.standarditaliani.it/pdf/STANDARD-2014-May28.pdf. Accessed December 16, 2014.
15. S.C. Gough Liraglutide: from clinical trials to clinical practice Diabetes Obes Metab 14 Suppl 2 2012 33 40
16. M. Evans, P. McEwan, R. OShea, and L. George A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice Diabetes Ther 4 2013 27 40
17. P. Ponzani Long-term effectiveness and safety of liraglutide in clinical practice Minerva Endocrinol 38 2013 103 112
18. E.L. Hannah Randomized Clinical Trials and Observational Studies: Guidelines for Assessing Respective Strengths and Limitations JACC Cardiovas Interv 1 2008 211 217
19. J.B. Buse, J. Rosenstock, and G. Sesti Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
20. M. Monami, I. Dicembrini, and N. Marchionni Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis Exp Diabetes Res 2012 2012 672658
21. G.P. Fadini, N. Simioni, and V. Frison Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients Acta Diabetol 50 2013 943 949
22. R.E. Van Genugten, D.L. Moller-Goede, D.H. van Raalte, and M. Diamant Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes Diabetes Obes Metab 15 2012 593 606
23. A. Garber, R.R. Henry, and R. Ratner Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes Diabetes Obes Metab 13 2011 348 356